IOVA wow, que market cap os sale ahora? en mi broker dice 3,5 en finviz 3,9 pero si calculo. 2,5bn ARK estan dentro a saco... se pone interesante, veremos si hoy compran, venden, o que hacen, y mañana a ver que tal
#129059
Re: Farmas USA
si fallaba el equipo de gestión la entrada de un nuevo CEO puede impulsarla IOVA
"Le haré una oferta que no rechazará" - Vito Corleone (Marlon Brando) El Padrino
#129061
Re: Farmas USA
Yo por el momento no me planteo entrada. Quizás más abajo pero no por el momento.NO es solo el problema el equipo de gestión. Es algo largo y complicado de explicar y técnico pero en resumen, no lo veo claro. LOL Si, ARK estaba dentro, esto y las criptos, le hacen un buen roto. Menuda rachita llevan IOVA
sixteen abstracts have been selected for virtual presentation, including one oral presentation, at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 4-8, 2021.
Key abstracts to be presented at the meeting will feature clinical data for XPOVIO® (selinexor), the Company's first in class, oral Selective Inhibitor of Nuclear Export (SINE) compound, including: (i) multiple new subgroup analyses from the pivotal Phase 3 BOSTON study, including data results evaluating XPOVIO treatment for patients over the age of 65 years old and patients with RAS-mutated multiple myeloma; (ii) updated data from the Pomalyst® (pomalidomide) and Kyprolis® (carfilzomib) arms of the Phase 1b/2 STOMP study evaluating XPOVIO in combination with backbone therapies in patients with relapsed or refractory multiple myeloma; (iii) new results from a Phase 1 study evaluating the combination of XPOVIO and pembrolizumab in advanced RAS mutant and RAS wild type colorectal cancer; (iv) results from gene set enrichment analyses identifying molecular predictors of response to XPOVIO from the Phase 2/3 SEAL study in patients with dedifferentiated liposarcoma (DDLS); and (v) updated overall survival (OS) data from a Phase 1/2 study evaluating oral eltanexor, the Company's second generation SINE compound, in patients with hypomethylating-agent refractory myelodysplastic syndrome (MDS).
Select Abstracts Featuring XPOVIO® (selinexor) in Multiple Myeloma
1. Title:Survival Among Older Patients with Previously Treated Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd) in the BOSTON study
Presenter: Thierry Facon, University Hospital Abstract #:8019 Date and time:Friday, June 4, 2021; 9:00 a.m. ET Session type: Poster Session:Hematologic Malignancies—Plasma Cell Dyscrasia Highlights: In an older patient population with a poor prognosis, XVd compared to Vd was associated with an OS benefit, improved progression-free survival (PFS) and an increased overall response rate (ORR) with reduced peripheral neuropathy and requires relatively short and infrequent clinic visits. XVd may be an effective regimen for patients 65 years of age or older. Adverse events (AEs) in this study were generally consistent with other previously reported selinexor studies in multiple myeloma.
2. Title: Effects of Weekly Selinexor, Bortezomib, Dexamethasone (XVd) Versus Standard Twice Weekly bortezomib and dexamethasone (Vd) on RAS-mutated previously treated multiple myeloma (MM)
Presenter: Christopher J. Walker, Karyopharm Therapeutics Inc. Abstract #: 8027 Date and time: Friday, June 4, 2021; 9:00 a.m. ET Session type: Poster Session: Hematologic Malignancies—Plasma Cell Dyscrasia Highlights: Despite typically having the worst outcomes, patients with MM with any (K-, H- or N-) RAS mutation had a similar benefit from XVd as RAS wild-type MM, showing that the XVd combination can overcome therapy resistance characteristic of RAS-mutated MM. Mechanistically, selinexor induced down regulation of germinal center kinase and enhanced killing of RAS-mutated MM cells. With a manageable safety profile, the XVd regimen was able to overcome the therapeutic resistance of RAS-mutated multiple myeloma and improved PFS and OS in patients with RAS-mutated MM, and the data suggest that selinexor-containing regimens could be active in other RAS-mutant cancers. AEs in this study were generally consistent with other previously reported selinexor studies in MM.
3. Title: Effects of Refractory Status to Lenalidomide on Safety and Efficacy of Selinexor, Bortezomib, and Dexamethasone (XVd) Versus Bortezomib and Dexamethasone (Vd) in Patients with Previously Treated Multiple Myeloma
Presenter: Xavier Leleu, CHU de Poitiers, Hôpital La Mileterie Abstract #: 8024 Date and time: Friday, June 4, 2021; 9:00 a.m. ET Session type: Poster Session: Hematologic Malignancies—Plasma Cell Dyscrasia Highlights: In patients with previously treated multiple myeloma, PFS, ORR, and time to next treatment were significantly improved regardless of documented refractory status to any immunomodulatory drug (IMiD) or to lenalidomide specifically. These analyses support the use of the XVd combination for patients with disease refractory to lenalidomide and likely to any IMiD. AEs in this study were generally consistent with other previously reported selinexor studies in multiple myeloma.
4. Title: Oral Selinexor, Pomalidomide, and Dexamethasone (XPd) at Recommended Phase 2 Dose in Relapsed Refractory Multiple Myeloma (MM)
Presenter: Darrell White, QEII Health Sciences Center, Dalhousie University Abstract #: 8018 Date and time: Friday, June 4, 2021; 9:00 a.m. ET Session type: Poster Discussion Presentation Session: Hematologic Malignancies—Plasma Cell Dyscrasia Highlights: Once-weekly selinexor was shown in this Phase 1b/2 study to be safely combined with Pomalyst® (pomalidomide) and low-dose dexamethasone (XPd) in patients with heavily pretreated MM. This all-oral XPd combination is highly active with an ORR of 65% at the recommended Phase 2 dose in 20 patients, compared to the expected ORR of ≤30% for the combination of Pomalyst® and dexamethasone (Pd) or selinexor and dexamethasone, and has thus far produced durable responses with a median PFS of 12.2 months. The data suggest that the regimen was active even in patients with daratumumab-refractory MM. AEs in this study were generally consistent with other previously reported selinexor studies in multiple myeloma.
5. Title: Once Weekly Selinexor, Carfilzomib, and Dexamethasone (XKd) in Carfilzomib Nonrefractory Multiple Myeloma (MM) Patients
Presenter: Cristina Gasparetto, Duke University Cancer Center Abstract #: 8038 Date and time: Friday, June 4, 2021; 9:00 a.m. ET Session type: Poster Session: Hematologic Malignancies—Plasma Cell Dyscrasia Highlights: In 27 patients with heavily pretreated MM (median of 4 lines of prior therapy), weekly XKd is highly active with an ORR of 78% and deep responses (≥VGPR 41%) with an overall PFS of 15 months; activity was strong even in patients with daratumumab refractory disease. AEs in this Phase 1/2b study were generally consistent with other previously reported selinexor studies in MM.
6. Title: Selinexor Containing Regimens in Patients with Multiple Myeloma (MM) Previously Treated with anti-CD38 Monoclonal Antibodies (aCD38 mAbs)
Presenter: Cristina Gasparetto, Duke University Cancer Center Abstract #: e20020 Session type: Online abstract Highlights: Selinexor-containing triplet combinations in 47 patients with MM previously treated with anti-CD38 mAb, most of whom had triple-class refractory MM, exhibit tolerability and comparable effectiveness to their most recent anti-CD38 mAb-containing regimens in this retrospective analysis. Compared to historical controls who did not receive selinexor, median OS was much longer among these patients. The results show that selinexor-containing regimens maintain high levels of anti-MM activity, even in patients whose disease is refractory to daratumumab, immunomodulatory drugs and proteasome inhibitors. AEs in this study were generally consistent with other previously reported selinexor studies in multiple myeloma.
Select Abstracts Featuring XPOVIO (selinexor) in Solid Tumors
7. Title: Molecular Predictors of Response to Selinexor in Advanced Unresectable De-differentiated Liposarcoma (DDLS)
Presenter: Christopher J. Walker, Karyopharm Therapeutics Inc. Abstract #: 11509 Date and time: Friday, June 4, 2021; 9:00 a.m. ET Session type: Oral presentation Session: Emerging Trends in Sarcoma Precision Medicine Highlights: The randomized Phase 3 SEAL study of selinexor versus placebo in patients with heavily pretreated DDLS showed a significant improvement in PFS for selinexor. The molecular analyses reported here demonstrate that DDLS tumors responding to selinexor showed low expression of CALB1 and high GRM1. If validated, patients with DDLS whose tumors match this expression profile are especially likely to benefit from selinexor.
8. Title: Open-Label Phase 1 Study Evaluating the Tolerability and Anti-Tumor Activity of Selinexor and Pembrolizumab in Colorectal Cancer
Presenter: Talia Golan, Oncology Department Center Sheba Medical Center at Tel Hashomer Session type: Online abstract Abstract #: e15579 Highlights: Selinexor in combination with pembrolizumab has demonstrated disease control in patients with chemotherapy refractory, advanced/metastatic, microsatellite stable colorectal cancer (CRC). Greater anti-tumor activity was observed in patients with RAS mutations despite the absence of high microsatellite instability and/or deficient in mismatch repair. The therapy was well tolerated with no unanticipated adverse events observed.
9. Title: Selinexor in Combination with Weekly Paclitaxel in Patients with Advanced or Metastatic Solid Tumors: Results of an Open Label, Single-Center, Multi-arm Phase 1b Study
Presenter: Shannon Westin, The University of Texas MD Anderson Cancer Center Abstract #: 5565 Date and time: Friday, June 4, 2021; 9:00 a.m. ET Session type: Poster Session: Gynecologic Cancer Highlights: Among 24 evaluable patients with heavily pretreated ovarian cancer, oral selinexor in combination with weekly paclitaxel resulted in an ORR of 17% and a clinical benefit rate (response + stable disease >12 weeks) of 58%. With prior taxane therapy, the ORR was 10% and with no prior taxane therapy, the ORR was 23%. The combination demonstrated promising clinical activity with manageable toxicity.
Abstracts Featuring Eltanexor in MDS
10. Title: Updated Overall Survival of Eltanexor for the Treatment of Patients with Hypomethylating Agent Refractory Myelodysplastic Syndrome
Presenter: Sangmin Lee, Weill Cornell Medical College Abstract #: e19037 Session type: Online abstract Highlights: Single-agent oral eltanexor was active in patients with high-risk, hypomethylating agent refractory MDS. Of the 20 enrolled patients, seven (35%) had marrow complete response (mCR), and five (25%) had stable disease (SD) for a total disease control (mCR+SD) rate of 60%. Of the 15 patients evaluable for efficacy, seven (47%) had mCR and five (33%) had SD. Patients who reached mCR (n=7) had significantly longer median OS than patients without mCR (n=8) or with progressive disease (n=3). Side effects were consistent with other studies of eltanexor without solid organ toxicity. Further evaluation of eltanexor in MDS as a single agent and in combination with other agents is ongoing.
Additional Abstracts to be Presented
11. Title: A Randomized, Open-label, Phase 3 Study of Low-dose Selinexor and Lenalidomide (Len) Versus Len Maintenance Post Autologous Stem Cell Transplant (ASCT) for Newly Diagnosed Multiple Myeloma (NDMM): ALLG MM23: Sealand
Presenter: Hang Quach, St. Vincent Hospital Abstract #: TPS8055 Date and time: Friday, June 4, 2021; 9:00 a.m. ET Session type: Poster Session: Hematologic Malignancies—Plasma Cell Dyscrasia
12. Title: U.S. Budget Impact (BI) Model for Selinexor, Bortezomib, and Dexamethasone (XVd) for the Treatment of Patients with Previously Treated Multiple Myeloma (MM)
Presenter: Mike Dolph, McGill University Abstract #: e18839 Session type: Online abstract
13. Title: SIENDO/ENGOT-EN5/GOG-3055: A Randomized Phase 3 Trial of Maintenance Selinexor Versus Placebo After Combination Platinum-based Chemotherapy in Advanced or Recurrent Endometrial Cancer
Presenter: Ignace Vergote, BGOG and University Hospitals Leuven, Leuven Cancer Institute Abstract #: TPS5610 Date and time: Friday, June 4, 2021; 9:00 a.m. ET Session type: Poster Session: Gynecologic Cancer
14. Title: A Phase 1/2 Study of Selinexor in Combination with Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Presenter: Yazmin Odia, Miami Cancer Institute, Baptist Health South Florida (BHSF) Abstract #: TPS2071 Date and time: Friday, June 4, 2021; 9:00 a.m. ET Session type: Poster Session: Central Nervous System Tumors
15. Title: Digital Measurement of Functional Status of Patients with Glioblastoma
Presenter: Yasaman Demastani, Karyopharm Therapeutics Inc. Abstract #: 2016 Date and time: Friday, June 4, 2021; 9:00 a.m. ET Session type: Poster Session: Central Nervous System Tumors
16. Title: A Phase 1b/2 Study of Selinexor in Combination with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor (GIST): SeliGIST/GEIS-41 Trial
Presenter: Cesar Serrano, West Virginia University School of Medicine Neurology & Neurosurgery Abstract #: 11534 Date and time: Friday, June 4, 2021; 9:00 a.m. ET Session type: Poster Session: Sarcoma
«Después de nada, o después de todo/ supe que todo no era más que nada.»
SPY salvado de nuevo por la MM50 y soporte de canal QQQ soporte de canal pero hay que reconquistar esa MM50 diaria para no empezar a pensar mal, eh? XBI y si mañana cerrara en la clavicular ( naranja ) ... podriamos tener estructura de iHCH ??... hmmmm ... el breakout haria romper la cuña
_foro.png?1621448238)
